Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
Proceedings of the National Academy of Sciences of the United States of America
|
October 26, 2005
Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1
Edward Htun van der Horst, Yan Y Degenhardt, Astrid Strelow, et al.
Communications Biology
|
May 24, 2026
A heterobifunctional IRAK4-targeting degrader impairs myddosome signaling in acute kidney injury and ameliorates kidney fibrosis
Marta Lopez-Marfil, Xichi Wang, Diana Ofelia Lopez-Cantu, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
December 12, 2025
Developmental Toxicology Profile of the IRAK4 Degrader KT-474
Bradley E Enerson, Gregg Cappon, Yatao Shi, et al.
Inflammatory Bowel Diseases
|
May 23, 2024
Challenges in IBD Research 2024: Preclinical Human IBD Mechanisms
Matthew A Ciorba, Liza Konnikova, Simon A Hirota, et al.
ACS Chemical Biology
|
April 3, 2019
Small Molecule and Pooled CRISPR Screens Investigating IL17 Signaling Identify BRD2 as a Novel Contributor to Keratinocyte Inflammatory Responses
Peter F Slivka, Chen-Lin Hsieh, Alex Lipovsky, et al.
Journal of Medicinal Chemistry
|
June 26, 2024
Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma
Matthew M Weiss, Xiaozhang Zheng, Nan Ji, et al.
Frontiers in Immunology
|
January 30, 2026
Targeted degradation of MK2 is insufficient to block inflammatory cytokine production in human cells due to cooperativity with MK3 and MK5
Bin Yang, Guoqiang Fang, Isaac Marx, et al.
Journal of Medicinal Chemistry
|
August 16, 2024
Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases
Xiaozhang Zheng, Nan Ji, Veronica Campbell, et al.
Nature Medicine
|
November 13, 2023
IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial
Lindsay Ackerman, Gerard Acloque, Sandro Bacchelli, et al.
The Journal of Experimental Medicine
|
February 28, 2020
A population of proinflammatory T cells coexpresses αβ and γδ T cell receptors in mice and humans
Sarah C Edwards, Caroline E Sutton, Kristin Ladell, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
Proceedings of the National Academy of Sciences of the United States of America
|
October 26, 2005
Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1
Edward Htun van der Horst, Yan Y Degenhardt, Astrid Strelow, et al.
Communications Biology
|
May 24, 2026
A heterobifunctional IRAK4-targeting degrader impairs myddosome signaling in acute kidney injury and ameliorates kidney fibrosis
Marta Lopez-Marfil, Xichi Wang, Diana Ofelia Lopez-Cantu, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
December 12, 2025
Developmental Toxicology Profile of the IRAK4 Degrader KT-474
Bradley E Enerson, Gregg Cappon, Yatao Shi, et al.
Inflammatory Bowel Diseases
|
May 23, 2024
Challenges in IBD Research 2024: Preclinical Human IBD Mechanisms
Matthew A Ciorba, Liza Konnikova, Simon A Hirota, et al.
ACS Chemical Biology
|
April 3, 2019
Small Molecule and Pooled CRISPR Screens Investigating IL17 Signaling Identify BRD2 as a Novel Contributor to Keratinocyte Inflammatory Responses
Peter F Slivka, Chen-Lin Hsieh, Alex Lipovsky, et al.
Journal of Medicinal Chemistry
|
June 26, 2024
Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma
Matthew M Weiss, Xiaozhang Zheng, Nan Ji, et al.
Frontiers in Immunology
|
January 30, 2026
Targeted degradation of MK2 is insufficient to block inflammatory cytokine production in human cells due to cooperativity with MK3 and MK5
Bin Yang, Guoqiang Fang, Isaac Marx, et al.
Journal of Medicinal Chemistry
|
August 16, 2024
Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases
Xiaozhang Zheng, Nan Ji, Veronica Campbell, et al.
Nature Medicine
|
November 13, 2023
IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial
Lindsay Ackerman, Gerard Acloque, Sandro Bacchelli, et al.
The Journal of Experimental Medicine
|
February 28, 2020
A population of proinflammatory T cells coexpresses αβ and γδ T cell receptors in mice and humans
Sarah C Edwards, Caroline E Sutton, Kristin Ladell, et al.
Page
of 2